Answers are grounded in this paper and cite their sources.
Evaluates aptamer selectivity toward oxidized low-density lipoprotein, suggesting effective biomolecular targeting.
High target selectivity is a crucial factor in aptamer performance and practical applicability. The selectivity of four DNA aptamers (AP07, AP11, AP25, and AP29) toward oxidized low-density lipoprotein (oxLDL) was examined through computational prediction and experimental validation. Molecular dynamics simulations, combined with molecular mechanics generalized Born surface area (MM/GBSA) analysis, were employed to evaluate binding preferences against apolipoprotein (apo) B100 (apoB100) of native low-density lipoprotein (LDL), oxidized apoB100 of oxLDL, apoA1 of high-density lipoprotein (HDL), apoC1/apoE of very-low-density lipoprotein (VLDL), and albumin. Among the candidates, AP11 revealed the strongest predicted affinity and selectivity toward oxidized apoB100, exhibiting the lowest binding free energies of −344.52 ± 18.37 kcal/mol. Experimental validation using an aptamer-based electrochemical assay confirmed the computational predictions, with AP11 displaying high selectivity for the entire oxLDL and cross-reactivity below 6% toward LDL, HDL, VLDL, and albumin. Structural analysis indicated that AP11 preserves key conformational motifs upon complex formation, contributing to the oxLDL–aptamer interaction. This integrated computational–experimental framework provides a robust strategy for evaluating and optimizing aptamer selectivity toward complex biomolecular targets.
No takes yet. Share an insight, caveat, or question.
Chunta et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: